Lifecore Capital Lease Obligations from 2010 to 2025
| LFCR Stock | 6.85 0.02 0.29% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 8.2 M | Current Value 12.9 M | Quarterly Volatility 8.7 M |
Check Lifecore Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lifecore Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 M, Interest Expense of 21.8 M or Total Revenue of 140.1 M, as well as many indicators such as Price To Sales Ratio of 0.2, Dividend Yield of 0.0 or PTB Ratio of 0.74. Lifecore financial statements analysis is a perfect complement when working with Lifecore Biomedical Valuation or Volatility modules.
Lifecore | Capital Lease Obligations |
Latest Lifecore Biomedical's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Lifecore Biomedical over the last few years. Lifecore Biomedical capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Lifecore Biomedical asset purchases. For example, Lifecore Biomedical can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Lifecore Biomedical control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Lifecore Biomedical's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lifecore Biomedical's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Lifecore Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 9,140,190 | |
| Geometric Mean | 6,548,603 | |
| Coefficient Of Variation | 95.48 | |
| Mean Deviation | 6,438,473 | |
| Median | 3,532,000 | |
| Standard Deviation | 8,726,951 | |
| Sample Variance | 76.2T | |
| Range | 27.3M | |
| R-Value | 0.49 | |
| Mean Square Error | 62T | |
| R-Squared | 0.24 | |
| Significance | 0.05 | |
| Slope | 898,684 | |
| Total Sum of Squares | 1142.4T |
Lifecore Capital Lease Obligations History
About Lifecore Biomedical Financial Statements
Lifecore Biomedical shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Lifecore Biomedical investors may analyze each financial statement separately, they are all interrelated. The changes in Lifecore Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lifecore Biomedical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 8.2 M | 12.9 M |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.